Literature DB >> 22719026

Preeclampsia and angiotensin converting enzyme (ACE) I/D and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms: association with ACE I/D polymorphism.

Zohreh Rahimi1, Ziba Rahimi, Hadi Mozafari, Abbas Parsian.   

Abstract

BACKGROUND: The aim of the present study was to investigate the association between angiotensin converting enzyme (ACE) insertion/deletion (I/D) and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms with the risk of preeclampsia and lipid peroxidation in preeclamptic women from Western Iran.
METHODS: One hundred and ninety-eight preeclamptic women (128 women with mild and 70 with severe forms) and 100 age- and parity-matched controls were enrolled in this case-control study.
RESULTS: The presence of D allele of ACE was associated with a 1.8-fold increased risk of preeclampsia (p=0.002) in total preeclamptic patients. The frequency of AT1R AC+CC genotypes was higher in mild preeclamptic women (32%) compared to controls (27.2%) (p>0.05). In mild preeclamptic women with ID genotype, the level of total antioxidant capacity (TAC) was significantly decreased compared to those with II genotype. Also, there was a trend toward increasing malondialdehyde (MDA) and decreasing TAC levels in mild and severe preeclamptic women with AT1R AA through CC genotypes.
CONCLUSIONS: Our study indicates that lipid peroxidation and oxidative stress are involved in the development of preeclampsia that might be influenced by polymorphism in the renin-angiotensin-aldosterone system genes.

Entities:  

Keywords:  ACE I/D; AT1R A1166C; MDA; Preeclampsia; TAC

Mesh:

Substances:

Year:  2012        PMID: 22719026     DOI: 10.1177/1470320312448950

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  9 in total

Review 1.  The Angiotensin-converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications.

Authors:  Christos Yapijakis; Iphigenia Gintoni; Maria Adamopoulou
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  ACE gene rs4343 polymorphism elevates the risk of preeclampsia in pregnant women.

Authors:  Atieh Abedin Do; Emran Esmaeilzadeh; Mona Amin-Beidokhti; Reihaneh Pirjani; Milad Gholami; Reza Mirfakhraie
Journal:  J Hum Hypertens       Date:  2018-08-20       Impact factor: 3.012

Review 3.  Pregnancy, Preeclampsia, and COVID-19: Susceptibility and Mechanisms: A Review Study.

Authors:  Babak Sayad; Zeinab Mohseni Afshar; Feizollah Mansouri; Mehdi Salimi; Ronak Miladi; Somayeh Rahimi; Zohreh Rahimi; Maria Shirvani
Journal:  Int J Fertil Steril       Date:  2022-05-08

Review 4.  ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy.

Authors:  Zohreh Rahimi
Journal:  J Nephropathol       Date:  2012-10-01

5.  AT1R A1166C variants in patients with type 2 diabetes mellitus and diabetic nephropathy.

Authors:  Mahmoudreza Moradi; Zohreh Rahimi; Sonia Amiri; Ziba Rahimi; Mahmood Vessal; Hamid Nasri
Journal:  J Nephropathol       Date:  2015-07-01

Review 6.  A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy.

Authors:  Zohreh Rahimi; Mahmoudreza Moradi; Hamid Nasri
Journal:  J Res Med Sci       Date:  2014-11       Impact factor: 1.852

7.  Distribution of ACE insertion/deletion (I/D) polymorphism in Iranian populations.

Authors:  Mostafa Saadat
Journal:  Mol Biol Res Commun       Date:  2015-06

8.  Genetic Association of Angiotensin-Converting Enzyme (ACE) Gene I/D Polymorphism with Preterm Birth in Korean Women: Case-Control Study and Meta-Analysis.

Authors:  Noo Ri Lee; In Wook Hwang; Hyung Jun Kim; Yun Dan Kang; Jin Wan Park; Han Jun Jin
Journal:  Medicina (Kaunas)       Date:  2019-06-10       Impact factor: 2.430

9.  Three polymorphisms of renin-angiotensin system and preeclampsia risk.

Authors:  Chen Wang; Xiao Zhou; Huai Liu; Shuhui Huang
Journal:  J Assist Reprod Genet       Date:  2020-11-23       Impact factor: 3.412

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.